Announcement PDF ASX ANNOUNCEMENT 10 May 2017 Interview with UK Chief Investigator in Cynata Clinical Trial Melbourne, Australia; 10 May 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has today released a webcast interview with Dr Adrian Bloor, UK Chief Investigator in Cynata’s Phase 1 clinical trial in acute steroid resistant graft-versus-host disease (GvHD). Dr Bloor is Consultant Haematologist at the Christie Hospital (The Christie NHS Foundation Trust) in Manchester, one of the largest cancer treatment centers in Europe. He is also clinical director of the stem cell transplantation programme, The Christie’s Clinical Trials Coordination Centre and an Honorary Clinical Senior Lecturer at the University of Manchester. In this webcast, Dr Bloor discusses: • • • The nature of GvHD; The potential utility of mesenchymal stem cells (MSCs) in treating this disease; and A progress update on Cynata’s Phase 1 clinical trial To listen to the webcast please click here: http://cynata.com/news/webcast-interview-with-uk-chiefinvestigator-in-gvhd-clinical-trial. Ends CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position. Cynata Therapeutics Limited Suite 1, 1233 High Street, Armadale, Victoria 3143, Australia PO Box 7165, Hawthorn North, Victoria 3122 T: + 613 9824 5254 F: + 613 9822 7735 E: admin@cynata.com ABN - 98 104 037 372